|
Patient and tumor characteristics |
|||
| Clinicopathological Features |
Patients n (%) |
Clinicopathological Features |
Patients n (%) |
|
|
|||
| Menopausal status |
T |
||
| Postmenopausal |
15 (25) |
TIS |
3 (5) |
| Premenopausal |
39 (66) |
pTx |
1 (2) |
| Unknown |
5 (9) |
pT1 |
19 (33) |
| Histotype |
pT2 |
22 (37) |
|
| Ductal invasive |
45 (76) |
pT3 |
2 (3) |
| Lobular invasive |
4 (7) |
pT4 |
12 (20) |
| Intraductal |
3 (5) |
Diameter (mm) |
|
| Inflammatory |
4 (7) |
≤ 10 mm |
9 (15) |
| Other |
3 (5) |
> 10 mm |
42 (71) |
| Grading |
Unknown |
8 (14) |
|
| G1 |
7 (12) |
||
| G2 |
18 (31) |
N |
|
| G3 |
26 (44) |
pN1-3 |
20 (34) |
| Unknown |
8 (13) |
pN4-10 |
9 (15) |
| Ki-67 |
pN > 10 |
4 (7) |
|
| 0–15% |
33 (56) |
Negative |
19 (32) |
| 16–25% |
9 (15) |
Unknown |
7 (12) |
| 26–100% |
14 (24) |
HER-2 |
|
| Unknown |
3 (5) |
Positive |
31 (53) |
| ER/PgR |
Negative |
28 (47) |
|
| ER+/PgR+ |
38 (64) |
||
| ER-/PgR- |
12 (20) |
LVI |
|
| ER+/PgR- |
7 (12) |
Positive |
27 (46) |
| ER-/PgR+ |
1 (2) |
Negative |
24 (41) |
| Unknown |
1 (2) |
Unknown |
8 (13) |
|
G, differentiation grade; G1-3, low, moderate or intermediate, high grade. ER, estrogen receptor alpha; PgR, progesterone receptor; T, tumor size; pT1, 0–2 cm; pT2, 2–5 cm; pT3, > 5 cm; pT4, ulcerated or attached; Tis, carcinoma in situ; pTX, primary tumor of unknown pT; N, node status; LVI, lymphovascular invasion; n, number of cases. | |||
Fiorio et al. BMC Cancer 2008 8:305 doi:10.1186/1471-2407-8-305 |
|||